8-K filed Sep 14, 2026 at 07:12 ET
Armata Pharmaceuticals announced FDA Breakthrough Therapy designation for AP-SA02, its intravenous phage therapy for complicated Staphylococcus aureus bacteremia (including MRSA). The designation is supported by Phase 1b/2a data showing 100% of AP-SA02 patients maintained clinical response at 28 days vs. 75% for placebo, and provides expedited FDA review, cross-disciplinary collaboration, and senior management engagement. This is a significant regulatory milestone that de-risks the Phase 3 program and enhances the asset's value, though the company remains pre-revenue with no financial data in this filing.